Intepirdine

Intepirdine (SB-742457) is a quinoline-based 5-HT6 receptor antagonist that was carried through more than a decade of clinical development, first by GlaxoSmithKline and then by Axovant Sciences as RVT-101. In a randomized, double-blind, placebo-controlled phase 2 study in mild-to-moderate Alzheimer's disease, the 35 mg dose produced a statistically significant benefit on the clinician's global impression of change (CIBIC+), with a supportive but non-significant trend on the ADAS-Cog cognitive scale ^[1].

On the strength of these and other mid-stage data, intepirdine advanced to the large phase 3 MINDSET trial, which randomized 1315 patients with mild-to-moderate Alzheimer's disease on stable donepezil to 35 mg per day or placebo for 24 weeks. MINDSET was unambiguously negative on both co-primary endpoints, cognition (ADAS-Cog) and daily function (ADCS-ADL), with a safety profile similar to placebo ^[2]. A parallel study in dementia with Lewy bodies also failed, and Axovant discontinued the programme.

Intepirdine is now cited alongside idalopirdine as the definitive clinical test of the 5-HT6 antagonist hypothesis for dementia ^[3]. Reviews of the class note the paradox that both 5-HT6 antagonists and agonists can enhance cognition in preclinical models, suggesting the receptor's pro-cognitive role is more nuanced than a simple on/off switch and helping explain the disappointing translational record.

Moderate clinical data; suggestive phase 2, definitively negative phase 3

Across phase 2 and phase 3 studies intepirdine was generally safe and well tolerated, with adverse events largely comparable to placebo and no defining organ-toxicity signal at the tested dose. Because it never demonstrated efficacy, its benefit-risk balance was ultimately judged unfavourable purely on lack of effect rather than on toxicity. It is investigational and discontinued, with no approved human dosing.

Discovered at GlaxoSmithKline as SB-742457, the compound was later acquired by Roivant subsidiary Axovant Sciences and rebranded RVT-101, becoming the centerpiece of one of the most watched neurology biotech stories of the mid-2010s. When the phase 3 MINDSET trial failed in September 2017, followed by a negative dementia-with-Lewy-bodies study, Axovant's valuation collapsed and the compound was abandoned.

Intepirdine is widely remembered as a cautionary tale in both drug development and biotech investing, illustrating how a plausible mechanism and a promising phase 2 can still yield a decisive phase 3 failure. Scientifically it remains a useful, well-characterized reference antagonist for 5-HT6 pharmacology.